MOUSE COMPLEMENT REGULATORY PROTEIN CRRY/P65 USES THE SPECIFIC MECHANISMS OF BOTH HUMAN DECAY-ACCELERATING FACTOR AND MEMBRANE COFACTOR PROTEIN

被引:192
作者
KIM, YU
KINOSHITA, T
MOLINA, H
HOURCADE, D
SEYA, T
WAGNER, LM
HOLERS, VM
机构
[1] UNIV COLORADO, HLTH SCI CTR, DEPT MED, DIV RHEUMATOL, DENVER, CO 80262 USA
[2] UNIV COLORADO, HLTH SCI CTR, DEPT IMMUNOL, DENVER, CO 80262 USA
[3] OSAKA UNIV, MICROBIAL DIS RES INST, DEPT IMMUNOREGULAT, SUITA, OSAKA 565, JAPAN
[4] WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63130 USA
[5] CTR ADULT DIS, OSAKA 537, JAPAN
关键词
D O I
10.1084/jem.181.1.151
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Normal host cells are protected from the destructive action of complement by cell. surface complement regulatory proteins. In humans, decay-accelerating factor (DAF) and membrane cofactor protein (MCP) play such a biologic role by inhibiting C3 and C5 convertases. DAF and MCP accomplish this task by specific mechanisms designated decay-accelerating activity and factor I cofactor activity, respectively. In other species, including mice, structural and/or functional homologues of these proteins are not yet well characterized. Previous studies have shown that the mouse protein Crry/p65 has certain characteristics of self-protecting complement regulatory proteins. For example, Crry/p65 is expressed on a wide variety of murine cells, and when expressed on human K562 erythroleukemic cells, it prevents deposition of mouse C3 fragments on the cell surface during activation of either the classical or alternative complement pathway. We have now studied factor I cofactor and decay-accelerating activities of Crry/p65. Recombinant Crry/p65 demonstrates cofactor activity for factor I-mediated cleavage of both mouse C3b and C4b. Surprisingly, Crry/p65 also exhibits decay-accelerating activity for the classical pathway C3 convertase strongly and for the alternative pathway C3 convertase weakly. Therefore, mouse Crry/p65 uses the specific mechanisms of both human MCP and DAF. Although Crry/p65, like MCP and DAF, contains tandem short consensus repeats (SCR) characteristic of C3/C4 binding proteins, Crry/p65 is not considered to be a genetic homologue of either MCP or DAF. Thus, Crry/p65 is an example of evolutionary conservation of two specific activities in a single unique protein in one species that are dispersed to individual proteins in another. We propose that the repeating SCR motif in this family has allowed this unusual process of evolution to occur, perhaps driven by the use of MCP and DAF as receptors by human pathogens such as the measles virus.
引用
收藏
页码:151 / 159
页数:9
相关论文
共 51 条
[41]  
PAUL MS, 1990, J IMMUNOL, V144, P1988
[42]  
POST TW, 1990, J IMMUNOL, V144, P740
[43]   PHYSIOLOGICAL RELEVANCE OF THE MEMBRANE ATTACK COMPLEX INHIBITORY PROTEIN CD59 IN HUMAN SEMINAL PLASMA - CD59 IS PRESENT ON EXTRACELLULAR ORGANELLES (PROSTASOMES), BINDS CELL-MEMBRANES, AND INHIBITS COMPLEMENT-MEDIATED LYSIS [J].
ROONEY, IA ;
ATKINSON, JP ;
KRUL, ES ;
SCHONFELD, G ;
POLAKOSKI, K ;
SAFFITZ, JE ;
MORGAN, BP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (05) :1409-1420
[44]  
ROSSE WF, 1992, CURR TOP MICROBIOL, V178, P163
[45]   COMPLEMENT-MEDIATED TUMOR-CELL DAMAGE INDUCED BY ANTIBODIES AGAINST MEMBRANE COFACTOR PROTEIN (MCP, CD46) [J].
SEYA, T ;
HARA, T ;
MATSUMOTO, M ;
SUGITA, Y ;
AKEDO, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (06) :1673-1680
[46]   PURIFICATION AND CHARACTERIZATION OF A MEMBRANE-PROTEIN (GP45-70) THAT IS A COFACTOR FOR CLEAVAGE OF C3B AND C4B [J].
SEYA, T ;
TURNER, JR ;
ATKINSON, JP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 163 (04) :837-855
[47]   3RD COMPONENT OF HUMAN COMPLEMENT - PURIFICATION FROM PLASMA AND PHYSICOCHEMICAL CHARACTERIZATION [J].
TACK, BF ;
PRAHL, JW .
BIOCHEMISTRY, 1976, 15 (20) :4513-4521
[48]  
TAKIZAWA H, 1994, J IMMUNOL, V152, P3032
[49]  
VIK DP, 1993, J IMMUNOL, V151, P6214
[50]   STRUCTURE OF THE HUMAN LYMPHOCYTE-B RECEPTOR FOR C3D AND THE EPSTEIN-BARR VIRUS AND RELATEDNESS TO OTHER MEMBERS OF THE FAMILY OF C3/C4 BINDING-PROTEINS [J].
WEIS, JJ ;
TOOTHAKER, LE ;
SMITH, JA ;
WEIS, JH ;
FEARON, DT .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 167 (03) :1047-1066